Grant of Options and Directors Dealing

C4X Discovery Holdings PLC

29 September 2023

 

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Grant of Options and Directors Dealing

29 September 2023 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that a total of 5,950,000 options over ordinary shares of the Company were awarded pursuant to the 2014 Share Option Plan to certain employees, which includes 400,000 options each to Dr Clive Dix, Chief Executive Officer, Brad Hoy, Chief Financial Officer and Bhavna Hunjan, Chief Business Officer as set out below.

Director	Position	Number of share options awarded	Option exercise price per share (pence)	Total number of options held
Dr Clive Dix	Chief Executive Officer	400,000	15.1	1,245,000
Brad Hoy	Chief Financial Officer	400,000	15.1	1,400,000
Bhavna Hunjan	Chief Business Officer	400,000	15.1	1,255,556

The options have an exercise price of 15.1 pence, being the average 5-day VWAP of the ordinary shares prior to the 29 September 2023.  The options can be exercised at any time between three and ten years of them being granted.

The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by person discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name(s)	Dr Clive Dix
2	Reason for the notification
a)	Position/status	Chief Executive Officer, Director
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	C4X Discovery Holdings plc
b)	LEI	213800UHNL82E323O870
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Options over ordinary shares of one penny (£0.01) each in the share capital of the Company - EMI 2014 Plan ISIN GB00BQQ2RV18
b)	Nature of the transaction	Grant of options over ordinary shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 15.1p 400,000
d)	Aggregated information
e)	Date of the transaction	29 September 2023
f)	Place of the transaction	London Stock Exchange - AIM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Brad Hoy
2	Reason for the notification
a)	Position/status	Chief Financial Officer, Director
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	C4X Discovery Holdings plc
b)	LEI	213800UHNL82E323O870
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Options over ordinary shares of one penny (£0.01) each in the share capital of the Company - EMI 2014 Plan ISIN GB00BQQ2RV18
b)	Nature of the transaction	Grant of options over ordinary shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 15.1p 400,000
d)	Aggregated information
e)	Date of the transaction	29 September 2023
f)	Place of the transaction	London Stock Exchange - AIM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Bhavna Hunjan
2	Reason for the notification
a)	Position/status	Chief Business Officer, Director
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	C4X Discovery Holdings plc
b)	LEI	213800UHNL82E323O870
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Options over ordinary shares of one penny (£0.01) each in the share capital of the Company - EMI 2014 Plan ISIN GB00BQQ2RV18
b)	Nature of the transaction	Grant of options over ordinary shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 15.1p 400,000
d)	Aggregated information
e)	Date of the transaction	29 September 2023
f)	Place of the transaction	London Stock Exchange - AIM

- Ends -

Contacts

C4X Discovery Holdings
Mo Noonan, Communications	[phone]
Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)	[phone]
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal	[phone]

Notes to Editors:

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.

 

END